World Vaccine Congress Lyon 2012 - list of video presentations 

 

 

Panel session: addressing significant unmet needs through world class vaccine pipelines › Mr Christian Moser, Head of Research, Pevion Biotech › Mr Matt Davis, Associate Professor of Pediatrics and Communicable Diseases, University of Michigan

New directions in EU vaccine research – some perspectives and prospects › Mr Andreas Holtel, DG RTD Health research, European Commission

Immunosafety of vaccines in the context of Innovative Medicines Initiative › Dr Maria Teresa de Magistris, Principal Scientific Manager, Innovative Medicines Initiative (IMI)

ADITEC: A technology-based approach to vaccine research and development › Prof Donata Medaglini, Associate Professor of Microbiology, Head of the Laboratory of Microbial Immunity in the Department of Biotechnology, University of Siena and Scalvo Vaccines Association

The EC FP7 ComplexINC project: New technologies and production tools for complex protein biologics › Dr Imre Berger, EMBL Group Leader, Principal Investigator, The European Molecular Biology Laboratory EMBL

The role of the European Vaccine Initiative today › Dr Odile Leroy, Executive Director, European Vaccine Initiative

UK vaccine policy and strategy – adapting to change › Dr Philip Minor, Division of Virology, National Institute for Biological Standards and Control (NIBSC)

Evolving immunisation program development and review › Mr Harald Heijbel, Department of Immunology and Vaccinology (retired), Swedish Institute for Infectious Disease Control

Taking action and a lead in coordinating public health › Prof.dr. M.C.J.P. Claire Boog, Head of Unit Vaccinology, RIVM/Cib, Netherlands Vaccine Institute

Understanding public trust in vaccination › Mr Angus Thomson, Director, Global Immunisation Policy, Sanofi Pasteur

Enabling manufacture of modern vaccines › Mr Olivier Loeillot, Head of Enterprise Solutions, GE Healthcare

The role of MVI PATH and the responsibility to the developing world › Dr Alex Adjagba, Program Officer - Health Econ and Policy, PATH Malaria Vaccine Initiative

The role of NGOs in Europe and globally › Dr Hansi Dean, Director, New Alliances, IAVI

Paradigm shifts: the future outlook for innovation in vaccines › Mr Christian Moser, Head of Research, Pevion Biotech

Overcoming challenges in process development and manufacturing of vaccines for clinical trials › Mr Stephen Cross, Process Development Scientist, Merck Millipore

New European initiatives on vaccines › Dr Odile Leroy, Executive Director, European Vaccine Initiative

Review of the 2010 World Health Organization recommendations for influenza vaccination composition › Dr Yipu Lin, Assistant Director, WHO Collaborating Centre for Reference and Research - Influenza

The changing regulatory landscape for influenza vaccines › Ed Geuns, Director Regulatory Affairs Vaccines EPD, Abbott Biologicals

'Flu programme' management within the UK › Prof David Salisbury, Director of Immunisation, UK Dept of Health

Communication efficacy across the vaccine delivery pipeline › Ms Heather Richmond, CDC Liaison, MedImmune

Case study for novel adjuvants as technology platforms – ISCOMATRIX® adjuvant › Debbie Drane, VP Business Development, CSL Ltd

Adjuvants - a strategic component in modern vaccine › Dr Karin Lovgren Bengtsson, Chief Scientific Officer, Isconova AB › Thomas Phillipson, Director, Business Development, Isconova

Human monoclonal antibodies against influenza: a map guiding towards a universal influenza vaccine? › Dr Jaap Goudsmit, CSO, Crucell

Panel session: moving towards the reality of a universal influenza vaccine › Dr. Melissa Malhame, Senior Director, Clinical Research, Dynavax › Dr Jaap Goudsmit, CSO, Crucell › Dr. Sarah Gilbert, Head of Study, Jenner Institute, Oxford University

Microbial Active Immuno-Therapy (MAIT): A Comprehensive Multi-Factorial Treatment Modality › John Rothman, Executive Vice President Science & Operations, Advaxis Inc

Collaborations and co-development between start-up biotech and big pharma › Mr John Trizzino, SVP Business Development, Novavax

Panel session: Universal influenza vaccine: what challenges must be overcome to ensure feasibility? › Dr Manon Cox, Chief Executive Officer, Protein Sciences Corporation › Dr. Melissa Malhame, Senior Director, Clinical Research, Dynavax